Skip to main content
. 2022 Sep 26;27(11):905–e848. doi: 10.1093/oncolo/oyac174

Table 3.

Objective response rate.

Patients, n (%) Treatment group Total
(N = 70)
A
(n = 9)
B
(n = 9)
C
(n = 11)
D
(n = 9)
E
(n = 13)
F
(n = 8)
G
(n = 11)
Best response
 Complete response 0 0 1 (9.1) 0 0 0 0 1 (1.4)
 Partial response 5 (55.6) 5 (55.6) 2 (18.2) 3 (33.3) 2 (15.4) 3 (37.5) 1 (9.1) 21 (30.0)
 Stable disease 2 (22.2) 2 (22.2) 7 (63.6) 4 (44.4) 2 (15.4) 2 (25.0) 4 (36.4) 23 (32.9)
 Progressive disease or death 2 (22.2) 2 (22.2) 0 2 (22.2) 9 (69.2) 3 (37.5) 6 (54.5) 24 (34.3)
 Not evaluable 0 0 1 (9.1) 0 0 0 0 1 (1.4)
Objective response rate 5 (55.6) 5 (55.6) 3 (27.3) 3 (33.3) 2 (15.4) 3 (37.5) 1 (9.1) 22 (31.4)